文献(101-200)
101. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by
Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging 2016; 17: 1321-1360. PMID: 27422899
102. Andersen OS, Smiseth OA, Dokainish H, et al. Estimating Left Ventricular Filling Pressure by Echocardiography. J Am Coll Cardiol
2017; 69: 1937-1948. PMID: 28408024
103. Donal E, Lund LH, Oger E, et al. KaRen investigators. Value of exercise echocardiography in heart failure with preserved ejection fraction:
a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging 2016; 17: 106-113. PMID: 26082167
104. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J 2016; 37: 2097-
2104. PMID: 27174289
105. Karamitsos TD, Francis JM, Myerson S, et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol
2009; 54: 1407-1424. PMID: 19796734
106. 日本循環器学会．肥大型心筋症の診療に関するガイドライン（2012年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2012_doi_h.pdf
107. 日本循環器学会．循環器病の診断と治療に関するガイドライン2011．拡張型心筋症ならびに関連する二次性心筋症の診療に関す
108. Babu-Narayan SV, Giannakoulas G, Valente AM, et al. Imaging of congenital heart disease in adults. Eur Heart J 2016; 37: 1182-1195.
PMID: 26424866
109. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular
Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn
Reson 2013; 15: 92-92. PMID: 24124732
110. Ghostine S, Caussin C, Habis M, et al. Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography. Eur
Heart J 2008; 29: 2133-2140. PMID: 18385120
111. 日本循環器学会．慢性虚血性心疾患の診断と病態把握のための検査法の選択基準に関するガイドライン（2010年改訂版）．
112. 日本循環器学会．循環器病の診断と治療に関するガイドライン．心臓核医学検査ガイドライン．Circ J 2005; 69 suppl IV: 1125-1202.
113. Bonow RO, Maurer G, Lee KL, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction.
N Engl J Med 2011; 364: 1617-1625. PMID: 21463153
114. Imamura Y, Ando H, Mitsuoka W, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity
in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26: 1594-1599. PMID: 7594091
115. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate
myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12:
1252-1258. PMID: 3170968
116. Matsuo S, Nakamura Y, Tsutamoto T, et al. Impairments of myocardial sympathetic activity may reflect the progression of myocardial
damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002; 9: 407-412. PMID: 12161717
117. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation
in patients with AL (primary) amyloidosis. Am Heart J 2002; 144: 122-129. PMID: 12094198
118. Tsutsui H, Ando S, Kubota T, et al. Abnormalities of cardiac sympathetic neuronal and left ventricular function in chronic mitral regurgitation:
assessment by iodine-123 metaiodobenzylguanidine scintigraphy. Am J Card Imaging 1996; 10: 14-22. PMID: 8680129
119. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic
innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013; 6: 772-784. PMID: 23845574
120. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol 2011; 18: 135-143. PMID:
21082300
121. Kasama S, Toyama T, Kurabayashi M. Usefulness of Cardiac Sympathetic Nerve Imaging Using (123)Iodine-Metaiodobenzylguanidine
Scintigraphy for Predicting Sudden Cardiac Death in Patients With Heart Failure. Int Heart J 2016; 57: 140-144. PMID: 26973278
122. Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of
iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141: 645-652. PMID:
11275933
123. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with
congestive heart failure. J Nucl Med 2002; 43: 1279-1285. PMID: 12368364
124. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:
1085-1089. PMID: 9225795
125. Maurer MS. Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. Am J Med 2015; 128:
1275-1280. PMID: 26091765
126. Høilund-Carlsen PF, Lauritzen SL, Marving J, et al. The reliability of measuring left ventricular ejection fraction by radionuclide cardiography:
evaluation by the method of variance components. Br Heart J 1988; 59: 653-662. PMID: 3395524
127. Sakata K, Yoshino H, Kurihara H, et al. Prognostic significance of persistent right ventricular dysfunction as assessed by radionuclide
angiocardiography in patients with inferior wall acute myocardial infarction. Am J Cardiol 2000; 85: 939-944. PMID: 10760330
128. Le Guludec D, Gauthier H, Porcher R, et al. Prognostic value of radionuclide angiography in patients with right ventricular arrhythmias.
Circulation 2001; 103: 1972-1976. PMID: 11306526
129. 日本循環器学会．循環器病ガイドラインシリーズ2016年度版．心臓サルコイドーシスの診療ガイドライン．
130. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and
metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241- 248. PMID: 22228794
131. The criteria committee of the New York Heart Association. In: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and
Great Vessels 9th edn. Little Brown & Co, 1994: 253-256.
132. Sasayama S, Asanoi H, Ishizaka S, et al. Evaluation of functional capacity of patients with congestive heart failure. In : Yasuda H,
Kawaguchi H, editors. New aspects in the treatment of failing heart syndrome. Springer-Verlag, 1992: 113-117.
133. 難病情報センター．特発性拡張型心筋症（指定難病５７）．http://www.nanbyou.or.jp/entry/3986
134. 大西洋三，佐藤秀幸，是恒之宏，他．6分間歩行試験の正常値の分布とその規定因子に関する検討．Jpn Circ J 1998; 61 (Suppl III):
856.
135. Bittner V, Weiner DH, Yusuf S, et al. SOLVD Investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients
with left ventricular dysfunction. JAMA 1993; 270: 1702-1707.PMID: 8411500
136. Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in
ambulatory outpatients with systolic heart failure. J Am Coll Cardiol2012; 60: 2653-2661. PMID: 23177293
137. Cheetham C, Taylor R, Burke V, et al. The 6-minute walk test does not reliably detect changes in functional capacity of patients awaiting
cardiac transplantation. J Heart Lung Transplant 2005; 24: 848-853.PMID: 15982612
138. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in
ambulatory patients with heart failure. Circulation 1991; 83: 778-786.PMID: 1999029
139. Nakanishi M, Takaki H, Kumasaka R, et al. Targeting of high peak respiratory exchange ratio is safe and enhances the prognostic power
of peak oxygen uptake for heart failure patients. Circ J 2014; 78: 2268-2275. PMID: 25056425
140. Koike A, Koyama Y, Itoh H, et al. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild
to moderate heart failure. Jpn Circ J 2000; 64: 915-920. PMID:11194282
141. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory
patients referred for cardiac transplant evaluation. Circulation1997; 95: 2660-2667. PMID: 9193435
142. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient
guidelines/prioritization.J Am Coll Cardiol 1993; 22: 21-31. PMID: 8509544
143. Fletcher GF, Ades PA, Kligfield P, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the
Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing,
and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American
Heart Association. Circulation 2013; 128: 873-934. PMID: 23877260
144. Matsumura N, Nishijima H, Kojima S, et al. Determination of anaerobic threshold for assessment of functional state in patients with
chronic heart failure. Circulation 1983; 68: 360-367. PMID: 6222847
145. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted
peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996; 27: 345-352. PMID: 8557904
146. Wasserman K, Hansen JE, Sue D. Physiology of Exercise. In: Principles of Exercise Testing and Interpretation. Lea & Febiger, 1994.
147. 日本循環器学会．心疾患患者の学校、職域、スポーツにおける運動許容条件に関するガイドライン（2008年改訂版）．
148. 日本循環器学会．心血管疾患におけるリハビリテーションに関するガイドライン（2012年改訂版）．
149. Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J
2004; 147: 354-360. PMID: 14760336
150. Kostis JB, Davis BR, Cutler J, et al. SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment
in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-216. PMID: 9218667
151. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl
J Med 2008; 358: 1887-1898. PMID: 18378519
152. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network
meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011; 171: 384-394. PMID:
21059964
153. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure
Control. N Engl J Med 2015; 373: 2103-2116. PMID: 26551272
154. 日本高血圧学会．高血圧治療ガイドライン2014．ライフサイエンス出版 2014.
155. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic
dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-588. PMID: 16905022
156. Pfeffer MA, Braunwald E, Moyé LA, et al. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-
677. PMID: 1386652
157. Køber L, Torp-Pedersen C, Carlsen JE, et al. Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-
converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;
333: 1670-1676. PMID: 7477219
158. Abdulla J, Barlera S, Latini R, et al. A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes
and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007; 9:
129-135. PMID: 16829187
159. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN
randomised trial. Lancet 2001; 357: 1385-1390. PMID: 11356434
160. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart
disease. J Card Fail 1997; 3: 249-254. PMID: 9547437
161. Scirica BM, Morrow DA, Cannon CP, et al. PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for
heart failure after an acute coronary syndrome in the PROVE ITTIMI 22 study. J Am Coll Cardiol 2006; 47: 2326-2331. PMID:
16750703
162. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative
meta-analysis of randomised controlled trials. Heart 2007; 93: 914- 921. PMID: 17277349
163. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardi al Infarction Heart Failure Efficacy and Survival Study Investigators.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;
348: 1309-1321. PMID: 12668699
164. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild
symptoms. N Engl J Med 2011; 364: 11-21. PMID: 21073363
165. Montalescot G, Pitt B, Lopez de Sa E, et al. REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation
myocardial infarction without heart failure: the Randomized Double- Blind Reminder Study. Eur Heart J 2014; 35: 2295-2302. PMID:
24780614
166. 日本循環器学会．心筋梗塞二次予防に関するガイドライン（2011年改訂版）．
167. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality
and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial
Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760. PMID: 12241832
168. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in
myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. PMID: 14610160
169. Hochman JS, Lamas GA, Buller CE, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after
myocardial infarction. N Engl J Med 2006; 355: 2395-2407. PMID: 17105759
170. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313. PMID: 12151467
171. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;
27: 1879-1884. PMID: 15277411
172. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men--morbidity, risk factors and prognosis. J
Intern Med 2001; 249: 253-261. PMID: 11285045
173. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004; 110:
1424-1430. PMID: 15353499
174. 日本糖尿病学会．糖尿病治療ガイド2016-2017．文光堂 2016.
175. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality
in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128. PMID: 26378978
176. Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients
with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526-1534.
PMID: 26819227
177. Fitchett D, Butler J, van de Borne P, et al. EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular
death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2018;
39: 363-370. PMID: 29020355
178. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in
Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. PMID: 28605608]
179. Dorans KS, Mostofsky E, Levitan EB, et al. Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish
men. Circ Heart Fail 2015; 8: 422-427. PMID: 25872788
180. Gonçalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study.
Eur Heart J 2015; 36: 939-945. PMID: 25602025
181. Gémes K, Janszky I, Ahnve S, et al. Light-to-moderate drinking and incident heart failure--the Norwegian HUNT study. Int J Cardiol
2016; 203: 553-560. PMID: 26569362
182. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435. PMID: 2883575
183. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left
ventricular ejection fractions. N Engl J Med 1992; 327: 685-691. PMID: 1463530
184. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med 1991; 325: 293-302. PMID: 2057034
185. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic
dysfunction: a follow-up study. Lancet 2003; 361: 1843-1848. PMID: 12788569
186. Matsumori A. Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of
oral candesartan cilexetil in patients with congestive heart failure.Eur J Heart Fail 2003; 5: 669-677. PMID: 14607207
187. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart
failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet 2003; 362: 772-776. PMID: 13678870
188. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:
randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587. PMID: 10821361
189. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717. PMID: 10471456
190. Tsutsui H, Ito H, Kitakaze M, et al. J-EMPHASIS-HF Study Group. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the
Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ J 2018; 82: 148-158. PMID:
28824029
191. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N
Engl J Med 2004; 351: 543-551. PMID: 15295047
192. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355. PMID: 8614419
193. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:
9-13. PMID: 10023943
194. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF) Lancet 1999; 353: 2001-2007. PMID: 10376614
195. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658. PMID: 11386263
196. Gattis WA, O’Connor CM, Gallup DS, et al. IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients
hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol
Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43: 1534-1541. PMID: 15120808
197. Fonarow GC, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or
withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;
52: 190-199. PMID: 18617067
198. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular
Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705-708. PMID: 12932605
199. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational
study using propensity score methods. Eur Heart J 2006; 27: 1431- 1439. PMID: 16709595
200. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97:
1759-1764. PMID: 16765130
急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）
ダイジェスト版